Tradestie Institutional Equity Comparison Engine

IBIO vs COCP โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

IBIO Overall Edge

IBIO Captures Institutional Edge (1โ€“1 Pillars ยท 4โ€“3 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to iBio, Inc. Common Stock (IBIO) driven by superior Growth & Margin while COCP counters with relative strength in Momentum & Technical. Fundamentally, IBIO trades at N/M Forward P/E with -3025.6% operating margin (+975.0% YoY revenue) versus COCP at N/M Forward P/E and -3063.6% operating margin (+26.9% YoY). In options structure, IBIO sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against COCP sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
IBIO N/M vs COCP N/M Fwd P/E
Growth & Margin Winner IBIO
Op Margin -3025.6% vs -3063.6% ยท YoY +975.0% vs +26.9%
Momentum & Technical Winner COCP
1Y -37.7% vs -3.0% ยท 52W Pos 1% vs 19%
Options & Structure Winner Tie
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (N/A IV)
IBIO NASDAQ
iBio, Inc. Common Stock
Pharmaceutical Preparations
$0.72
-2.04% 1D
Market Cap $53.7M
1M Return -6.46%
1Y Return -37.67%
Forward P/E N/M
Unified AI Score
46.0 / 100 HOLD
Tech 45.0 Fund 46.0 Flow 50.0 Mom 64.0
COCP NASDAQ
Cocrystal Pharma, Inc. Common Stock
Pharmaceutical Preparations
$1.00
+1.98% 1D
Market Cap $19.6M
1M Return -2.01%
1Y Return -2.96%
Forward P/E N/M
Unified AI Score
47.1 / 100 HOLD
Tech 51.0 Fund 48.0 Flow 50.0 Mom 54.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: IBIO -37.67% COCP -2.96% Spread: +34.71 pp (COCP Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period IBIO Revenue COCP Revenue IBIO Op. Margin COCP Op. Margin Margin Edge
FY2018 $0M N/A -3204.3% N/A IBIO
FY2019 $0M $10M -782.4% -737.4% COCP
FY2020 $0M $0M -854.9% -476.0% COCP
FY2021 $0M N/A -1312.1% N/A IBIO
FY2022 $0M N/A -1576.3% N/A IBIO
FY2024 $0M N/A -7392.9% N/A IBIO
FY2025 $0M N/A -4650.5% N/A IBIO
FY2026 $0M N/A -35141.0% N/A IBIO

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: IBIO (4) vs COCP (3)
Institutional Metric IBIO COCP Criterion Row Winner
Market Capitalization Scale $53.7M $19.6M Larger Scale IBIO
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +975.0% +26.9% Higher Growth IBIO
Operating Margin (TTM) Profitability -3025.6% -3063.6% Higher Margin IBIO
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -51.8% -311.7% Higher ROE IBIO
52-Week Range Position Momentum 1% ($1โ€“$4) 19% ($1โ€“$2) Stronger Trend COCP
Beta / 30D Volatility Risk Regime 2.07ฮฒ ยท 89% Vol 1.04ฮฒ ยท 54% Vol Lower Realized Risk COCP
Unified Institutional Score Composite Signal 46.0 / 100 (HOLD) 47.1 / 100 (HOLD) Higher Composite COCP

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full IBIO vs COCP Buy Guide
IBIO UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live IBIO Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
COCP UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live COCP Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither IBIO nor COCP registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.